Shell Asset Management Co. Trims Stock Position in Abbott Laboratories $ABT

Shell Asset Management Co. decreased its stake in Abbott Laboratories (NYSE:ABT) by 90.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,818 shares of the healthcare product maker’s stock after selling 104,215 shares during the period. Shell Asset Management Co.’s holdings in Abbott Laboratories were worth $1,449,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. IMG Wealth Management Inc. lifted its holdings in shares of Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after purchasing an additional 167 shares during the last quarter. Cloud Capital Management LLC acquired a new position in Abbott Laboratories during the third quarter worth approximately $29,000. Guerra Advisors Inc purchased a new stake in Abbott Laboratories in the third quarter valued at approximately $31,000. Anfield Capital Management LLC boosted its holdings in shares of Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares during the period. Finally, Delos Wealth Advisors LLC acquired a new position in shares of Abbott Laboratories in the 2nd quarter valued at $32,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Up 1.0%

ABT opened at $112.63 on Monday. The business has a 50 day simple moving average of $119.48 and a 200-day simple moving average of $126.39. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $141.23. The stock has a market capitalization of $195.84 billion, a P/E ratio of 30.28, a P/E/G ratio of 1.79 and a beta of 0.75. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The company had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the company earned $1.34 earnings per share. Abbott Laboratories’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, February 13th. Investors of record on Thursday, January 15th were issued a $0.63 dividend. The ex-dividend date was Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s payout ratio is currently 67.74%.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, February 4th. The shares were purchased at an average cost of $108.73 per share, with a total value of $1,087,300.00. Following the purchase, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.46% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on ABT shares. Citigroup lowered their price objective on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Royal Bank Of Canada lowered their price target on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Evercore dropped their price target on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. The Goldman Sachs Group lowered their target price on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Finally, Oppenheimer cut their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $137.05.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.